Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Baxter
Cerilliant
Cantor Fitzgerald
Moodys
QuintilesIMS
Julphar
Accenture

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,741,523

« Back to Dashboard

Summary for Patent: 5,741,523
Title: Stabilized prostaglandin E1
Abstract:A stable and lyophilized formulation of prostaglandin E-1 made by the process comprising a) dissolving PGE-1 in a solution of lactose and tertiary butyl alcohol wherein said tertiary butyl alcohol is present in an amount of from about 15% to about 33% volume/volume and the ratio of said lactose to PGE-1 is from about 40,000 to 1 to about 10,000 to 1 weight/weight whereby a formulation of PGE-1dispersed in lactose is formed; b) adjusting and maintaining the pH of said formulation from about 3.5 to about 6 with an organic acid buffer; c) freezing said formulation to about -50.degree. C.; and d) drying said formulation to obtain a moisture content of less than 1% by dry weight and a tertiary butyl alcohol content of less than 3% by dry weight. Preferably, step c) includes after freezing said formulation to about -50.degree. C., warming to about -25.degree. C. for about 2 hours then refreezing to about 50.degree. C. Preferably, the prostaglandin is in an amount of about 25 to 100 ppm in lactose and the pH is maintained at about 4 to 5.
Inventor(s): Teagarden; Dirk L. (Kalamazoo, MI), Petre; William J. (Kalamazoo, MI), Gold; Paul M. (Vicksburg, MI)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:08/619,690
Patent Claim Types:
see list of patent claims
Formulation; Process;

Drugs Protected by US Patent 5,741,523

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,741,523

PCT Information
PCT FiledSeptember 06, 1994PCT Application Number:PCT/US94/09648
PCT Publication Date:May 04, 1995PCT Publication Number: WO95/11683

International Family Members for US Patent 5,741,523

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1133561 ➤ Try a Free Trial
China 1060042 ➤ Try a Free Trial
Germany 69421936 ➤ Try a Free Trial
Denmark 0725642 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Fuji
Colorcon
Citi
Cerilliant
US Department of Justice
Federal Trade Commission
Accenture
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.